查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1848905

新生儿筛检市场按技术、检测类型、最终用户和样本类型划分－全球预测，2025-2032年

Newborn Screening Market by Technology, Test Type, End User, Sample Type - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，新生儿筛检市场规模将成长 21.3 亿美元，复合年增长率为 9.06%。

关键市场统计数据
基准年 2024 10.6亿美元
预计年份：2025年 11.6亿美元
预测年份 2032 21.3亿美元
复合年增长率 (%) 9.06%

全面概述技术融合、临床重点和营运限制如何重塑新生儿筛检项目

新生儿筛检在预防性儿科保健中发挥着至关重要的作用，它能够早期发现对终身健康影响深远的先天性疾病。近年来，诊断方法已从单一检测发展到多项检测法和基因组分析，这迫使临床医生、实验室技术人员和政策制定者重新思考筛检路径和基础设施。因此，相关人员必须权衡临床敏感性和特异性与操作可行性、样本物流以及扩展基因组数据所涉及的伦理问题。

随着技术与临床实践的融合，实验室网路和终端用户面临新的整合挑战。虽然干血斑检体仍然是许多计画的基石，但基于血清的检测和分子工作流程如今已成为传统方法的补充，有时甚至取代了传统方法。这种转变对检体采集、低温运输管理以及后续分析（这些分析为诊断确认和治疗性介入提供资讯）都具有实际意义。

此外，监管机构的期望和支付方的监督日益关注结果和成本效益，这推动了对可靠证据产生和标准化品质框架的需求。因此，医疗系统和供应商必须通力合作，优化通讯协定、培训和资料收集，以确保在保护病患隐私和知情同意的同时，实现可靠的人群筛检。最终，对当前新生儿筛检现状的策略性实施凸显了科学、政策和营运之间的相互作用，而这将决定下一代筛检计画的发展方向。

对正在重塑新生儿筛检服务模式的技术、资料管治和相关人员协作方面的转变进行策略性分析

新生儿筛检领域正在发生变革，这主要得益于分析平台、生物资讯学以及相关人员期望的快速发展。串联式质谱质谱和次世代定序仪等高解析度技术拓宽了诊断范围，使得以往难以常规检测的代谢和遗传疾病能够早期被发现。同时，免疫测量灵敏度和分子检测技术的进步缩短了检测週期，优化了确认流程，使筛检结果在新生儿护理中更具实用价值。

同时，数位健康工具与实验室资讯系统的整合改善了数据管理，促进了自动标记、纵向追踪以及筛检与后续护理之间更紧密的协调。这些进展，加上统一的品质指标和对能力验证的日益重视，增强了人们对扩大筛检范围的信心。此外，公共卫生机构和临床网路正在重新审视筛检范围和知情同意模式，以便在应对伦理问题的同时，更好地利用基因组学发现。

最后，仪器製造商、试剂供应商、临床实验室和支付方之间伙伴关係的兴起，促进了创新技术的扩散和规模化应用。因此，那些优先考虑互通性、可扩展工作流程和临床医生参与的机构，将更有利于应对这项变革，并将自身的技术能力转化为新生儿预后的改善。

对近期关税变动和贸易政策变化如何影响新生儿筛检的供应连续性、筹资策略和营运韧性进行基于证据的评估。

全球贸易环境中的政策调整和关税措施可能会对新生儿筛检系统产生连锁反应，影响诊断设备、耗材和试剂的供应和成本结构。随着进口关税的增加，实验室和医疗机构可能面临更长的采购週期和更高的资本设备及一次性试剂套件的单位成本，这反过来又会对其营运预算和筹资策略造成压力。为此，一些机构可能会优先考虑供应商多元化、寻求本地製造合作伙伴或重新谈判服务合同，以维持检测服务的连续性。

同时，不断上涨的投入成本可能会加速维护和生命週期管理实践的普及，从而提高仪器的可用性并减少停机时间。例如，实验室可以加强预防性保养计划，投资培训以提升内部技术能力，并在所有测试平台上采用标准化耗材，以实现规模经济。此外，采购团队可以优先考虑总体拥有成本分析和多年供应协议，以应对关税波动。

重要的是，无论关税如何波动，监管合规和品质保证要求仍将继续影响供应商的选择。因此，儘管政策制定者和行业相关人员在适应不断变化的贸易环境，但首要关注点仍将是维持诊断准确性、交付时间和新生儿筛检的公平可及性。从长远来看，贸易政策的转变可能会促使某些製造能力的资源配置，并促进区域供应链生态系统的发展，从而在不降低临床标准的前提下增强韧性。

这是一项以细分市场为导向的、主导凝聚力的分析，它解释了技术选择、测试组合、最终用户工作流程和检体模式如何相互作用，从而决定采用路径和营运设计。

细分市场洞察揭示了临床需求、技术能力和终端使用者工作流程的交汇点，从而塑造了产品开发和服务交付的策略重点。在各种技术模式中，高效液相层析继续发挥独特的分析作用；免疫测量平台可用于蛋白质生物标记的高通量筛检；聚合酵素链锁反应和桑格测序等分子技术能够实现快速靶向基因确认；次世代定序仪可构建更广泛的基因组检测和用于发现新基因；串联式质谱质谱法仍然是多重代谢筛检的核心。将这些平台结合起来，可以建立一个分层诊断架构，其中快速、低成本的筛检能够引导出更具特异性的分子和基因组确认流程。

就检测类型而言，针对囊肿纤维化、内分泌疾病、血红蛋白病和先天性代谢缺陷等疾病的传统筛检，由于其临床紧迫性高，因此维持着既定的诊疗路径。这些检测类别会影响检测方法的验证要求、检体处理通讯协定和临床追踪流程。同时，最终用户——诊断实验室、医院/诊所和研究实验室——也有着不同的焦点。诊断实验室强调检测通量、认证和成本控制；医院/诊所强调临床整合和及时报告结果；而研究实验室则优先考虑检测方法的灵活性和数据丰富性，以支持转化研究。

血清检体虽然可以用于某些定量和确证性检测，但其采集和处理流程与传统血清样本有所不同。因此，能够使平台功能与特定检测项目、最终用户限制和检体物流相符的供应商和实验室管理者，将推动血清样本的普及和临床效用。

从细緻入微的区域观点探讨司法管辖政策、基础设施成熟度和供应链所在地如何影响新生儿筛检计画的设计和永续性。

区域动态对新生儿筛检计画的设计、监管预期和供应链韧性有显着影响。在美洲，公共卫生计画通常强调标准化筛检方案，并辅以集中式实验室网路和公私合作医疗机构，以促进规模经济和整合筹资策略。儘管政策和投资的转型阶段激发了人们对基因组附加元件和试验计画的兴趣，但相关人员必须权衡扩大筛选规模与公平性和后续护理能力之间的关係。

同时，欧洲、中东和非洲呈现异质性环境，监管体系、医疗资金筹措和基础建设成熟度差异巨大。儘管先进的分析平台和全面的确诊途径在资源丰富的地区日益普及，但资源匮乏的地区则优先考虑稳健、低复杂度的检测方法和培训，以扩大基础医疗服务的覆盖范围。跨国合作和能力建构措施在缩小差距和促进技术转移方面发挥关键作用。

亚太地区实验室网路的快速现代化和强大的国内生产能力正在加速先进筛检方法的应用。然而，由于报销模式和人群健康优先事项的差异，部署策略也各不相同，一些经济体正在试点基因组整合，而另一些则专注于优化现有的生化筛检。总体而言，区域策略必须考虑监管协调、供应链多元化以及对劳动力发展的投资，以确保专案的永续扩展。

策略性地整合推动新生儿筛检供应商格局的竞争行动，重点在于互通性、证据生成、策略联盟和卓越服务。

产业参与者之间的竞争动态体现了对技术差异化、策略联盟以及服务和支援的重视，以满足临床和实验室需求。主要仪器製造商致力于透过工作流程自动化提高平台互通性并加快结果出具速度，而试剂供应商则优先考虑批间一致性和符合法规要求的文檔，以满足认证要求。同时，实验室服务供应商和参考网路致力于扩展确诊检测能力并制定标准化诊疗路径，以最大限度地缩短诊断和治疗时间。

策略活动还包括技术供应商与临床网路之间的伙伴关係，以检验扩展的检测组合；以及与学术中心的合作，以完善变异解读框架和证据产生。此外，各公司正投入资源进行培训计画和远端支持，以降低分散实验室的技术门槛，并确保各站点品质的一致性。併购和联盟持续重塑供应商格局，拓展产品系列和分销网络，同时为整合仪器、耗材、软体和资讯服务的整合解决方案创造机会。

这些企业策略总体上强调可靠性、扩充性和监管合规性。那些能够平衡创新与清晰的临床检验路径以及强有力的上市后支持的组织，将保持竞争优势，并与公共卫生计画和医疗服务提供者建立更紧密的伙伴关係。

领导者可以采取切实可行的策略要务，以加速推广应用、确保供应弹性，并建立将筛检进展与临床结果联繫起来的品质框架。

产业领导者必须采取切实可行的措施，将技术前景转化为营运和临床影响，同时应对政策和供应链的复杂性。首先，透过投资可互通的检测资讯系统和标准化报告格式，并确保筛检结果顺利整合到电子健康记录和人群健康登记系统中，从而加强后续追踪和结果评估的连续性。其次，优先发展人才队伍，资助实践培训、远端支援和能力评估，以确保实验室和临床医生能够应用不断发展的检测方法并解读复杂的基因检测观察。

接下来，我们将拓展多元化的供应商关係，并探索区域性製造或经销伙伴，以减少采购中断并降低贸易波动风险。同时，我们将实施生命週期管理实践，提高设备运作，并使维护计画与临床需求模式相符。此外，我们将积极与监管机构和支付方合作，共同设计实证研究，以证明其临床效用、真实世界表现和卫生经济学意义，同时解决与基因组筛检相关的伦理问题。

最后，应推行合作模式，将供应商、实验室、临床医生和公共卫生机构聚集在一起，试行整合式照护路径和数据共用倡议。透过将商业性策略与临床重点和系统层面的目标相结合，领导者可以加快推广应用，保持诊断质量，并显着改善新生儿健康状况。

采用透明的多来源调查方法，结合文献综述、专家参与和迭代检验，确保新生儿筛检结果的可靠性和可操作性。

本调查方法结合了系统性的二手文献综述、针对专家的定向一手研究以及严谨的资料三角验证，以确保研究结果的有效性和适用性。首先，研究方法整合了同行评审文献、监管指导文件、技术白皮书和会议论文集，以梳理当前技术水平、临床指南和操作实践。这为识别关键主题和知识缺口奠定了调查方法，以便透过一手研究进行更深入的探索。

主要研究包括对实验室主任、临床遗传学家、采购专业人员和公共卫生相关人员进行结构化访谈，以了解实际应用经验、痛点和策略重点。此外，也与供应商进行了讨论，探讨了产品蓝图、检验方法和服务模式。所有回应均经过匿名化处理和最后覆核，以避免偏见，确保结论尽可能反映共识，并在适当情况下反映不同观点。

最后，我们采用迭代三角测量法，将定性见解与文献证据进行比对；品管包括专家对技术说明的检验以及对不同资料来源的一致性检查。调查方法强调透明度，详细记录了纳入和排除标准、访谈通讯协定以及检验步骤，以确保研究结果的可重复性，并促进对已报告研究结果的知情应用。

简洁扼要的总结强调了将技术创新、营运准备和公平的专案设计相结合，以释放新生儿筛检益处的必要性。

总之，新生儿筛检领域正处于曲折点，分析创新、数据整合和策略合作能够显着改善早期发现率，并提升受影响儿童的长期预后。从串联式质谱质谱和高效液相层析法到标靶分子检测和广谱基因组序列测定，各项技术进步为实验室和医疗系统提供了互补的能力，可应用于筛检流程。然而，要真正实现临床获益，需要具备完善的营运准备、符合监管要求，并在不同地区和医疗机构之间实现公平的医疗服务取得。

展望未来，相关人员必须优先考虑互通性、人力资源能力以及与监管机构和支付方开展基于证据的合作，以确保扩大筛检范围能够带来可衡量的健康改善，同时又不降低品质或加剧健康差距。随着贸易动态和政策变化影响设备和耗材的获取，供应链的韧性和采购的灵活性仍然至关重要。专注于诸如多元化采购、维护产品生命週期、标准化报告和协作检验等切实可行的措施，可以帮助各组织在推进专案目标的同时降低风险。

最终，临床需求、技术机会和系统层面的承诺相结合，为新生儿筛检取得实质进展创造了契机。那些将策略与营运执行和以患者为中心的结果相结合的相关人员，最能将创新转化为持续的公共卫生影响。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 扩大用于检测新生儿罕见遗传疾病的次世代定序平台
  • 将数位健康平台整合到新生儿筛检中，实现即时数据共用和后续追踪
  • 官民合作关係促进了新生儿筛检基础设施在全国服务不足地区的扩展
  • 引入就地检验解决方案，以加速农村诊所代谢性疾病的检测速度
  • 协调政策和报销框架，以支持各州统一的新生儿筛检
  • 新型代谢体学学生物标记能够对新生儿筛检
  • 利用人工智慧演算法解读新生儿筛检中复杂的基因组变异

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 按技术分類的新生儿筛检市场

  • 高效液相层析
  • 免疫检测
  • 分子技术
    • 聚合酵素链锁反应
    • 桑格定序
  • 次世代定序
  • 串联式质谱

第九章新生儿筛检市场（依检测类型划分）

  • 囊肿纤维化
  • 内分泌疾病
  • 血红素疾病
  • 先天性代谢缺陷

第十章新生儿筛检市场（按最终用户划分）

  • 诊断实验室
  • 医院和诊所
  • 实验室

第十一章新生儿筛检市场（依样本类型划分）

  • 干涸的血迹
  • 血清样本

第十二章 各地区新生儿筛检市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章新生儿筛检市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 各国新生儿筛检市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • PerkinElmer, Inc.
    • Thermo Fisher Scientific Inc.
    • Danaher Corporation
    • Agilent Technologies, Inc.
    • Waters Corporation
    • Abbott Laboratories
    • Bio-Rad Laboratories, Inc.
    • BioMerieux SA
    • Siemens Healthineers AG
    • Shimadzu Corporation
Product Code: MRR-501246436EC1

The Newborn Screening Market is projected to grow by USD 2.13 billion at a CAGR of 9.06% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 1.06 billion
Estimated Year [2025] USD 1.16 billion
Forecast Year [2032] USD 2.13 billion
CAGR (%) 9.06%

A definitive contextual overview of how technological convergence, clinical priorities, and operational constraints are reshaping newborn screening programs

Newborn screening occupies a pivotal role in preventive pediatric healthcare by enabling early detection of congenital conditions that can profoundly affect lifelong outcomes. Over recent years, the diagnostic landscape has evolved from single-analyte assays toward multiplexed platforms and genomics-enabled workflows, prompting clinicians, laboratorians, and policy makers to reassess screening pathways and infrastructure. Consequently, stakeholders must balance clinical sensitivity and specificity with operational feasibility, sample logistics, and ethical considerations surrounding expanded genomic data.

As technology converges with clinical practice, laboratory networks and end users face novel integration challenges. Dried blood spot specimens remain foundational for many programs, yet serum-based assays and molecular workflows now complement and sometimes supplant traditional approaches. This shift has practical implications for specimen collection, cold chain management where applicable, and the downstream analytics that inform diagnostic confirmation and therapeutic interventions.

Moreover, regulatory expectations and payer scrutiny increasingly emphasize outcomes and cost-effectiveness, driving demand for robust evidence generation and standardized quality frameworks. Therefore, health systems and suppliers must collaborate to optimize protocols, training, and data capture to ensure reliable population-level screening while preserving patient privacy and informed consent. Ultimately, a strategic introduction to the current state of newborn screening highlights the interplay of science, policy, and operational execution that will define next-generation programs

A strategic analysis of the sweeping technological, data governance, and stakeholder collaboration shifts that are redefining newborn screening delivery models

The newborn screening landscape is undergoing transformative shifts driven by rapid advances in analytical platforms, bioinformatics, and stakeholder expectations. High-resolution techniques such as tandem mass spectrometry and next-generation sequencing have expanded diagnostic breadth, enabling earlier identification of metabolic and genetic disorders that previously eluded routine detection. At the same time, improvements in immunoassay sensitivity and molecular assays have reduced turnaround times and improved confirmatory workflows, making screening results more actionable in neonatal care settings.

Concurrently, the integration of digital health tools and laboratory information systems has elevated data management, facilitating automated flagging, longitudinal tracking, and tighter linkage between screening and follow-up care. These developments are accompanied by increasing emphasis on harmonized quality metrics and proficiency testing, which together reinforce trust in expanded screening panels. Moreover, public health authorities and clinical networks are revisiting screening panels and consent models to accommodate genomic findings while managing ethical implications.

Finally, the rise of collaborative partnerships across instrument manufacturers, reagent suppliers, clinical laboratories, and payers supports innovation diffusion and scale-up. As a result, organizations that prioritize interoperability, scalable workflows, and clinician engagement will navigate this transformation most effectively, positioning themselves to translate technical capability into improved neonatal outcomes

An evidence-based appraisal of how recent tariff shifts and trade policy changes can influence supply continuity, procurement strategies, and operational resilience in newborn screening

Policy adjustments and tariff measures introduced in global trade environments can ripple through the newborn screening ecosystem by affecting the availability and cost structure of diagnostic instruments, consumables, and reagents. When import tariffs rise, laboratories and healthcare providers may confront longer procurement cycles and elevated unit costs for capital equipment and single-use kits, which in turn can pressure operational budgets and procurement strategies. In response, some organizations may prioritize supplier diversification, seek localized manufacturing partners, or renegotiate service contracts to preserve continuity of testing services.

At the same time, higher input costs can accelerate adoption of maintenance and lifecycle management practices that extend equipment usability and reduce downtime. For example, laboratories may intensify preventive maintenance scheduling, invest in training that broadens in-house technical capabilities, and adopt standardized consumables across testing platforms to achieve economies of scale. Additionally, procurement teams may increase emphasis on total cost of ownership analyses and multi-year supply agreements to buffer against tariff volatility.

Importantly, regulatory compliance and quality assurance requirements will continue to shape supplier selection regardless of tariff dynamics. Therefore, while policymakers and industry participants adapt to evolving trade conditions, the primary focus remains on preserving diagnostic accuracy, turnaround time, and equitable access to newborn screening. In the longer term, shifts in trade policy may incentivize reshoring of certain manufacturing capabilities and foster regional supply ecosystems that enhance resilience without compromising clinical standards

A cohesive segmentation-driven analysis explaining how technology choices, test portfolios, end-user workflows, and specimen modalities interact to determine adoption pathways and operational design

Insight into segmentation illuminates where clinical need, technological capability, and end-user workflows intersect, shaping strategic priorities for product development and service delivery. Across technology modalities, High Performance Liquid Chromatography continues to serve niche analytical roles while Immunoassay platforms provide high-throughput screening for protein biomarkers; Molecular Techniques comprising Polymerase Chain Reaction and Sanger Sequencing deliver targeted, rapid genetic confirmation; Next Generation Sequencing enables broader genomic panels and discovery applications; and Tandem Mass Spectrometry remains central for multiplex metabolic screening. Taken together, these platforms create a layered diagnostic architecture where rapid, low-cost screens feed into more specific molecular or genomic confirmatory pipelines.

Regarding test types, traditional screens for conditions such as cystic fibrosis, endocrine disorders, hemoglobinopathies, and inborn errors of metabolism maintain high clinical urgency and established care pathways. These test categories influence assay validation requirements, specimen handling protocols, and clinical follow-up algorithms. In parallel, end users across diagnostic laboratories, hospitals and clinics, and research laboratories have distinct priorities: diagnostic laboratories emphasize throughput, accreditation, and cost control; hospitals and clinics focus on clinical integration and timely result reporting; and research laboratories prioritize assay flexibility and data richness for translational studies.

Sample type considerations further shape operational design, as dried blood spot specimens support broad population screening with logistical simplicity and archival stability, while serum samples enable certain quantitative assays and confirmatory testing that require different collection and processing workflows. Consequently, vendors and laboratory managers who align platform capabilities with specific test portfolios, end-user constraints, and specimen logistics will drive adoption and clinical utility

A nuanced regional perspective on how jurisdictional policy, infrastructure maturity, and supply chain localization shape newborn screening program design and sustainability

Regional dynamics exert pronounced influence on program design, regulatory expectations, and supply chain resilience in newborn screening initiatives. In the Americas, public health programs often emphasize standardized screening panels supported by centralized laboratory networks and a mix of public and private providers, which encourages scale economies and consolidated procurement strategies. Transitional phrases in policy and investment have increased interest in genomic add-ons and pilot programs, but stakeholders must balance expansion with equity and follow-up care capacity.

Meanwhile, Europe, Middle East & Africa present heterogeneous landscapes where regulatory regimes, healthcare financing, and infrastructure maturity vary widely. In well-resourced jurisdictions, advanced analytical platforms and comprehensive confirmatory pathways are increasingly common, whereas resource-limited settings prioritize robust, low-complexity assays and training to expand basic coverage. Cross-border collaborations and capacity-building initiatives play a key role in narrowing gaps and enabling technology transfer.

Across Asia-Pacific, rapid modernization of laboratory networks and strong domestic manufacturing capabilities support accelerating adoption of advanced screening modalities. However, diverse reimbursement models and population health priorities mean that rollout strategies differ, with some economies piloting genomic integration while others focus on optimizing existing biochemical screening. Overall, regional strategy must account for regulatory harmonization, supply chain diversification, and investments in workforce development to ensure sustainable program expansion

A strategic synthesis of competitive behaviors emphasizing interoperability, evidence generation, strategic alliances, and service excellence that drive the newborn screening vendor landscape

Competitive dynamics among industry participants reflect a blend of technological differentiation, strategic partnerships, and emphasis on service and support to meet clinical and laboratory needs. Leading instrument manufacturers focus on enhancing platform interoperability and reducing time-to-result through workflow automation, while reagent suppliers prioritize lot-to-lot consistency and regulatory-compliant documentation to support accreditation requirements. In parallel, laboratory service providers and reference networks concentrate on scaling confirmatory testing capacity and developing standardized care pathways that minimize time to diagnosis and treatment initiation.

Strategic activity also includes partnerships between technology vendors and clinical networks to validate expanded panels, as well as collaborations with academic centers to refine variant interpretation frameworks and evidence generation. Furthermore, companies are directing resources toward training programs and remote support capabilities to reduce technical barriers for decentralized laboratories and to ensure consistent quality across sites. Mergers and alliances continue to shape the supplier landscape, enabling broader product portfolios and distribution reach while creating opportunities for integrated solutions that bundle instruments, consumables, software, and data services.

Collectively, these corporate strategies emphasize reliability, scalability, and regulatory alignment. Organizations that balance innovation with clear pathways for clinical validation and robust post-market support will sustain competitive advantage and foster stronger partnerships with public health programs and healthcare providers

Actionable strategic imperatives for leaders to accelerate adoption, secure supply resilience, and embed quality frameworks that translate screening advances into clinical outcomes

Industry leaders must adopt pragmatic steps to convert technological promise into operational and clinical impact while navigating policy and supply chain complexities. First, invest in interoperable laboratory informatics and standardized reporting formats to ensure that screening results integrate smoothly into electronic health records and population health registries, thereby strengthening follow-up continuity and outcome measurement. Second, prioritize workforce development by funding hands-on training, remote support, and competency assessments so that laboratories and clinicians can reliably implement evolving assays and interpret complex genetic findings.

Next, cultivate diversified supplier relationships and explore regional manufacturing or distribution partnerships to mitigate procurement disruptions and reduce exposure to trade variability. Simultaneously, embed lifecycle management practices that extend equipment uptime and align maintenance schedules with clinical demand patterns. In parallel, engage proactively with regulatory bodies and payers to co-design evidence generation studies that demonstrate clinical utility, real-world performance, and health-economic implications while addressing ethical concerns related to genomic screening.

Finally, pursue collaborative models that link vendors, laboratories, clinicians, and public health entities to pilot integrated care pathways and data-sharing initiatives. By aligning commercial strategy with clinical priorities and system-level goals, leaders can accelerate adoption, preserve diagnostic quality, and deliver measurable improvements in neonatal health outcomes

A transparent, multi-source research methodology combining literature synthesis, expert engagement, and iterative validation to ensure robust and actionable newborn screening insights

The research approach combines systematic secondary literature review, targeted primary engagement with domain experts, and rigorous data triangulation to ensure validity and applicability of insights. Initially, the methodology synthesized peer-reviewed literature, regulatory guidance documents, technical whitepapers, and conference proceedings to map the technology landscape, clinical guidelines, and operational practices. This provided a foundation for identifying key themes and knowledge gaps that warranted further investigation through primary research.

Primary engagement comprised structured interviews with laboratory directors, clinical geneticists, procurement specialists, and public health officials to capture real-world implementation experiences, pain points, and strategic priorities. In addition, vendor discussions explored product roadmaps, validation practices, and service models. Responses were anonymized and cross-checked to avoid bias and to ensure that conclusions reflect consensus where possible and divergent views where appropriate.

Finally, iterative triangulation reconciled qualitative insights with documented evidence, and quality controls included validation of technical descriptions by subject-matter experts and consistency checks across data sources. The methodology emphasized transparency by documenting inclusion and exclusion criteria, interview protocols, and validation steps to support reproducibility and to facilitate informed use of the report's findings

A concise synthesis underscoring the imperative to align technological innovation, operational readiness, and equitable program design to unlock newborn screening benefits

In conclusion, the newborn screening landscape stands at an inflection point where analytical innovation, data integration, and strategic collaboration can materially improve early detection and long-term outcomes for affected infants. Technological advances-from tandem mass spectrometry and high-performance chromatography to targeted molecular assays and broader genomic sequencing-offer complementary capabilities that laboratories and health systems can deploy in layered screening pathways. Yet, realizing clinical benefit depends on operational readiness, regulatory alignment, and equitable access across regions and care settings.

Moving forward, stakeholders must prioritize interoperability, workforce capacity, and evidence-based engagement with regulatory and payer entities to ensure that expanded screening delivers measurable health improvements without compromising quality or exacerbating disparities. Supply chain resilience and procurement agility remain essential as trade dynamics and policy shifts influence access to instruments and consumables. By focusing on pragmatic measures-such as diversified sourcing, lifecycle maintenance, standardized reporting, and collaborative validation-organizations can mitigate risk while advancing programmatic goals.

Ultimately, the combination of clinical need, technological opportunity, and system-level commitment creates a window for meaningful progress in newborn screening. Stakeholders who align strategy with operational execution and patient-centered outcomes will be best positioned to translate innovation into enduring public health impact

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Expansion of next-generation sequencing panels to detect rare genetic disorders in newborns
  • 5.2. Integration of digital health platforms for real time data sharing and follow up in newborn screening
  • 5.3. Public private partnerships driving nationwide expansions of newborn screening infrastructure in underserved regions
  • 5.4. Adoption of point of care testing solutions to accelerate metabolic disorder detection in rural clinics
  • 5.5. Harmonization of policies and reimbursement frameworks to support uniform newborn screening across states
  • 5.6. Emerging metabolomic biomarkers enabling broader multiplex newborn screening for inborn errors of metabolism
  • 5.7. Utilization of artificial intelligence algorithms for interpreting complex genomic variants in neonatal screening

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Newborn Screening Market, by Technology

  • 8.1. High Performance Liquid Chromatography
  • 8.2. Immunoassay
  • 8.3. Molecular Techniques
    • 8.3.1. Polymerase Chain Reaction
    • 8.3.2. Sanger Sequencing
  • 8.4. Next Generation Sequencing
  • 8.5. Tandem Mass Spectrometry

9. Newborn Screening Market, by Test Type

  • 9.1. Cystic Fibrosis
  • 9.2. Endocrine Disorders
  • 9.3. Hemoglobin Disorders
  • 9.4. Inborn Errors Of Metabolism

10. Newborn Screening Market, by End User

  • 10.1. Diagnostic Laboratories
  • 10.2. Hospitals And Clinics
  • 10.3. Research Laboratories

11. Newborn Screening Market, by Sample Type

  • 11.1. Dried Blood Spot
  • 11.2. Serum Sample

12. Newborn Screening Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Newborn Screening Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Newborn Screening Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. PerkinElmer, Inc.
    • 15.3.2. Thermo Fisher Scientific Inc.
    • 15.3.3. Danaher Corporation
    • 15.3.4. Agilent Technologies, Inc.
    • 15.3.5. Waters Corporation
    • 15.3.6. Abbott Laboratories
    • 15.3.7. Bio-Rad Laboratories, Inc.
    • 15.3.8. BioMerieux SA
    • 15.3.9. Siemens Healthineers AG
    • 15.3.10. Shimadzu Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL NEWBORN SCREENING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NEWBORN SCREENING MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL NEWBORN SCREENING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NEWBORN SCREENING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS NEWBORN SCREENING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA NEWBORN SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA NEWBORN SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA NEWBORN SCREENING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE NEWBORN SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST NEWBORN SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA NEWBORN SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC NEWBORN SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL NEWBORN SCREENING MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN NEWBORN SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC NEWBORN SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION NEWBORN SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS NEWBORN SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 NEWBORN SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO NEWBORN SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL NEWBORN SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NEWBORN SCREENING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. NEWBORN SCREENING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. NEWBORN SCREENING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL NEWBORN SCREENING MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL NEWBORN SCREENING MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL NEWBORN SCREENING MARKET SIZE, BY HIGH PERFORMANCE LIQUID CHROMATOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL NEWBORN SCREENING MARKET SIZE, BY HIGH PERFORMANCE LIQUID CHROMATOGRAPHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL NEWBORN SCREENING MARKET SIZE, BY HIGH PERFORMANCE LIQUID CHROMATOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL NEWBORN SCREENING MARKET SIZE, BY HIGH PERFORMANCE LIQUID CHROMATOGRAPHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL NEWBORN SCREENING MARKET SIZE, BY HIGH PERFORMANCE LIQUID CHROMATOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL NEWBORN SCREENING MARKET SIZE, BY HIGH PERFORMANCE LIQUID CHROMATOGRAPHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL NEWBORN SCREENING MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL NEWBORN SCREENING MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL NEWBORN SCREENING MARKET SIZE, BY IMMUNOASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL NEWBORN SCREENING MARKET SIZE, BY IMMUNOASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL NEWBORN SCREENING MARKET SIZE, BY IMMUNOASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL NEWBORN SCREENING MARKET SIZE, BY IMMUNOASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL NEWBORN SCREENING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL NEWBORN SCREENING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL NEWBORN SCREENING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL NEWBORN SCREENING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL NEWBORN SCREENING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL NEWBORN SCREENING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL NEWBORN SCREENING MARKET SIZE, BY SANGER SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL NEWBORN SCREENING MARKET SIZE, BY SANGER SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL NEWBORN SCREENING MARKET SIZE, BY SANGER SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL NEWBORN SCREENING MARKET SIZE, BY SANGER SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL NEWBORN SCREENING MARKET SIZE, BY SANGER SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL NEWBORN SCREENING MARKET SIZE, BY SANGER SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL NEWBORN SCREENING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL NEWBORN SCREENING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL NEWBORN SCREENING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL NEWBORN SCREENING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL NEWBORN SCREENING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL NEWBORN SCREENING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL NEWBORN SCREENING MARKET SIZE, BY TANDEM MASS SPECTROMETRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL NEWBORN SCREENING MARKET SIZE, BY TANDEM MASS SPECTROMETRY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL NEWBORN SCREENING MARKET SIZE, BY TANDEM MASS SPECTROMETRY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL NEWBORN SCREENING MARKET SIZE, BY TANDEM MASS SPECTROMETRY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL NEWBORN SCREENING MARKET SIZE, BY TANDEM MASS SPECTROMETRY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL NEWBORN SCREENING MARKET SIZE, BY TANDEM MASS SPECTROMETRY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL NEWBORN SCREENING MARKET SIZE, BY CYSTIC FIBROSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL NEWBORN SCREENING MARKET SIZE, BY CYSTIC FIBROSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL NEWBORN SCREENING MARKET SIZE, BY CYSTIC FIBROSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL NEWBORN SCREENING MARKET SIZE, BY CYSTIC FIBROSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL NEWBORN SCREENING MARKET SIZE, BY CYSTIC FIBROSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL NEWBORN SCREENING MARKET SIZE, BY CYSTIC FIBROSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL NEWBORN SCREENING MARKET SIZE, BY ENDOCRINE DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL NEWBORN SCREENING MARKET SIZE, BY ENDOCRINE DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL NEWBORN SCREENING MARKET SIZE, BY ENDOCRINE DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL NEWBORN SCREENING MARKET SIZE, BY ENDOCRINE DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL NEWBORN SCREENING MARKET SIZE, BY ENDOCRINE DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL NEWBORN SCREENING MARKET SIZE, BY ENDOCRINE DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL NEWBORN SCREENING MARKET SIZE, BY HEMOGLOBIN DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL NEWBORN SCREENING MARKET SIZE, BY HEMOGLOBIN DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL NEWBORN SCREENING MARKET SIZE, BY HEMOGLOBIN DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL NEWBORN SCREENING MARKET SIZE, BY HEMOGLOBIN DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL NEWBORN SCREENING MARKET SIZE, BY HEMOGLOBIN DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL NEWBORN SCREENING MARKET SIZE, BY HEMOGLOBIN DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL NEWBORN SCREENING MARKET SIZE, BY INBORN ERRORS OF METABOLISM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL NEWBORN SCREENING MARKET SIZE, BY INBORN ERRORS OF METABOLISM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL NEWBORN SCREENING MARKET SIZE, BY INBORN ERRORS OF METABOLISM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL NEWBORN SCREENING MARKET SIZE, BY INBORN ERRORS OF METABOLISM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL NEWBORN SCREENING MARKET SIZE, BY INBORN ERRORS OF METABOLISM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL NEWBORN SCREENING MARKET SIZE, BY INBORN ERRORS OF METABOLISM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL NEWBORN SCREENING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL NEWBORN SCREENING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL NEWBORN SCREENING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL NEWBORN SCREENING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL NEWBORN SCREENING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL NEWBORN SCREENING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL NEWBORN SCREENING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL NEWBORN SCREENING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL NEWBORN SCREENING MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL NEWBORN SCREENING MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL NEWBORN SCREENING MARKET SIZE, BY HOSPITALS AND CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL NEWBORN SCREENING MARKET SIZE, BY HOSPITALS AND CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL NEWBORN SCREENING MARKET SIZE, BY HOSPITALS AND CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL NEWBORN SCREENING MARKET SIZE, BY HOSPITALS AND CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL NEWBORN SCREENING MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL NEWBORN SCREENING MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL NEWBORN SCREENING MARKET SIZE, BY RESEARCH LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL NEWBORN SCREENING MARKET SIZE, BY RESEARCH LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL NEWBORN SCREENING MARKET SIZE, BY RESEARCH LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL NEWBORN SCREENING MARKET SIZE, BY RESEARCH LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL NEWBORN SCREENING MARKET SIZE, BY DRIED BLOOD SPOT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL NEWBORN SCREENING MARKET SIZE, BY DRIED BLOOD SPOT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL NEWBORN SCREENING MARKET SIZE, BY DRIED BLOOD SPOT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL NEWBORN SCREENING MARKET SIZE, BY DRIED BLOOD SPOT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL NEWBORN SCREENING MARKET SIZE, BY DRIED BLOOD SPOT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL NEWBORN SCREENING MARKET SIZE, BY DRIED BLOOD SPOT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL NEWBORN SCREENING MARKET SIZE, BY SERUM SAMPLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL NEWBORN SCREENING MARKET SIZE, BY SERUM SAMPLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL NEWBORN SCREENING MARKET SIZE, BY SERUM SAMPLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL NEWBORN SCREENING MARKET SIZE, BY SERUM SAMPLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL NEWBORN SCREENING MARKET SIZE, BY SERUM SAMPLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL NEWBORN SCREENING MARKET SIZE, BY SERUM SAMPLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL NEWBORN SCREENING MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL NEWBORN SCREENING MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. AMERICAS NEWBORN SCREENING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 114. AMERICAS NEWBORN SCREENING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 115. AMERICAS NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 116. AMERICAS NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 117. AMERICAS NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2018-2024 (USD MILLION)
  • TABLE 118. AMERICAS NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2025-2032 (USD MILLION)
  • TABLE 119. AMERICAS NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 120. AMERICAS NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 121. AMERICAS NEWBORN SCREENING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 122. AMERICAS NEWBORN SCREENING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 123. AMERICAS NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 124. AMERICAS NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA NEWBORN SCREENING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. NORTH AMERICA NEWBORN SCREENING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 128. NORTH AMERICA NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2018-2024 (USD MILLION)
  • TABLE 130. NORTH AMERICA NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2025-2032 (USD MILLION)
  • TABLE 131. NORTH AMERICA NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 132. NORTH AMERICA NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA NEWBORN SCREENING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 134. NORTH AMERICA NEWBORN SCREENING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 136. NORTH AMERICA NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA NEWBORN SCREENING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. LATIN AMERICA NEWBORN SCREENING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 140. LATIN AMERICA NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2018-2024 (USD MILLION)
  • TABLE 142. LATIN AMERICA NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2025-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 144. LATIN AMERICA NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 145. LATIN AMERICA NEWBORN SCREENING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 146. LATIN AMERICA NEWBORN SCREENING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 148. LATIN AMERICA NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA NEWBORN SCREENING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA NEWBORN SCREENING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2018-2024 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2025-2032 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA NEWBORN SCREENING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA NEWBORN SCREENING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 161. EUROPE NEWBORN SCREENING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. EUROPE NEWBORN SCREENING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. EUROPE NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 164. EUROPE NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 165. EUROPE NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2018-2024 (USD MILLION)
  • TABLE 166. EUROPE NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2025-2032 (USD MILLION)
  • TABLE 167. EUROPE NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 168. EUROPE NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 169. EUROPE NEWBORN SCREENING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 170. EUROPE NEWBORN SCREENING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 171. EUROPE NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 172. EUROPE NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 173. MIDDLE EAST NEWBORN SCREENING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. MIDDLE EAST NEWBORN SCREENING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. MIDDLE EAST NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 176. MIDDLE EAST NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 177. MIDDLE EAST NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2018-2024 (USD MILLION)
  • TABLE 178. MIDDLE EAST NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2025-2032 (USD MILLION)
  • TABLE 179. MIDDLE EAST NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 180. MIDDLE EAST NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 181. MIDDLE EAST NEWBORN SCREENING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 182. MIDDLE EAST NEWBORN SCREENING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 183. MIDDLE EAST NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 184. MIDDLE EAST NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 185. AFRICA NEWBORN SCREENING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. AFRICA NEWBORN SCREENING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. AFRICA NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 188. AFRICA NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 189. AFRICA NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2018-2024 (USD MILLION)
  • TABLE 190. AFRICA NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2025-2032 (USD MILLION)
  • TABLE 191. AFRICA NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 192. AFRICA NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 193. AFRICA NEWBORN SCREENING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 194. AFRICA NEWBORN SCREENING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 195. AFRICA NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 196. AFRICA NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 197. ASIA-PACIFIC NEWBORN SCREENING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. ASIA-PACIFIC NEWBORN SCREENING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. ASIA-PACIFIC NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 200. ASIA-PACIFIC NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 201. ASIA-PACIFIC NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2018-2024 (USD MILLION)
  • TABLE 202. ASIA-PACIFIC NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2025-2032 (USD MILLION)
  • TABLE 203. ASIA-PACIFIC NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 204. ASIA-PACIFIC NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 205. ASIA-PACIFIC NEWBORN SCREENING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 206. ASIA-PACIFIC NEWBORN SCREENING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 207. ASIA-PACIFIC NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 208. ASIA-PACIFIC NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL NEWBORN SCREENING MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL NEWBORN SCREENING MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 211. ASEAN NEWBORN SCREENING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. ASEAN NEWBORN SCREENING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. ASEAN NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 214. ASEAN NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 215. ASEAN NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2018-2024 (USD MILLION)
  • TABLE 216. ASEAN NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2025-2032 (USD MILLION)
  • TABLE 217. ASEAN NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 218. ASEAN NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 219. ASEAN NEWBORN SCREENING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 220. ASEAN NEWBORN SCREENING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 221. ASEAN NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 222. ASEAN NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 223. GCC NEWBORN SCREENING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. GCC NEWBORN SCREENING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. GCC NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 226. GCC NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 227. GCC NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2018-2024 (USD MILLION)
  • TABLE 228. GCC NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2025-2032 (USD MILLION)
  • TABLE 229. GCC NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 230. GCC NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 231. GCC NEWBORN SCREENING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 232. GCC NEWBORN SCREENING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 233. GCC NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 234. GCC NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 235. EUROPEAN UNION NEWBORN SCREENING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPEAN UNION NEWBORN SCREENING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPEAN UNION NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPEAN UNION NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 239. EUROPEAN UNION NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2018-2024 (USD MILLION)
  • TABLE 240. EUROPEAN UNION NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2025-2032 (USD MILLION)
  • TABLE 241. EUROPEAN UNION NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 242. EUROPEAN UNION NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 243. EUROPEAN UNION NEWBORN SCREENING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPEAN UNION NEWBORN SCREENING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 245. EUROPEAN UNION NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 246. EUROPEAN UNION NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 247. BRICS NEWBORN SCREENING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. BRICS NEWBORN SCREENING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. BRICS NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 250. BRICS NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 251. BRICS NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2018-2024 (USD MILLION)
  • TABLE 252. BRICS NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2025-2032 (USD MILLION)
  • TABLE 253. BRICS NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 254. BRICS NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 255. BRICS NEWBORN SCREENING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 256. BRICS NEWBORN SCREENING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 257. BRICS NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 258. BRICS NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 259. G7 NEWBORN SCREENING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 260. G7 NEWBORN SCREENING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 261. G7 NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 262. G7 NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 263. G7 NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2018-2024 (USD MILLION)
  • TABLE 264. G7 NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2025-2032 (USD MILLION)
  • TABLE 265. G7 NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 266. G7 NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 267. G7 NEWBORN SCREENING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 268. G7 NEWBORN SCREENING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 269. G7 NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 270. G7 NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 271. NATO NEWBORN SCREENING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 272. NATO NEWBORN SCREENING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 273. NATO NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 274. NATO NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 275. NATO NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2018-2024 (USD MILLION)
  • TABLE 276. NATO NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2025-2032 (USD MILLION)
  • TABLE 277. NATO NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 278. NATO NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 279. NATO NEWBORN SCREENING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 280. NATO NEWBORN SCREENING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 281. NATO NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 282. NATO NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 283. GLOBAL NEWBORN SCREENING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 284. GLOBAL NEWBORN SCREENING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 285. UNITED STATES NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 286. UNITED STATES NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 287. UNITED STATES NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2018-2024 (USD MILLION)
  • TABLE 288. UNITED STATES NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2025-2032 (USD MILLION)
  • TABLE 289. UNITED STATES NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 290. UNITED STATES NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 291. UNITED STATES NEWBORN SCREENING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 292. UNITED STATES NEWBORN SCREENING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 293. UNITED STATES NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 294. UNITED STATES NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 295. CANADA NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 296. CANADA NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 297. CANADA NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2018-2024 (USD MILLION)
  • TABLE 298. CANADA NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2025-2032 (USD MILLION)
  • TABLE 299. CANADA NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 300. CANADA NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 301. CANADA NEWBORN SCREENING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 302. CANADA NEWBORN SCREENING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 303. CANADA NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 304. CANADA NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 305. MEXICO NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 306. MEXICO NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 307. MEXICO NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2018-2024 (USD MILLION)
  • TABLE 308. MEXICO NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2025-2032 (USD MILLION)
  • TABLE 309. MEXICO NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 310. MEXICO NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 311. MEXICO NEWBORN SCREENING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 312. MEXICO NEWBORN SCREENING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 313. MEXICO NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 314. MEXICO NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 315. BRAZIL NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 316. BRAZIL NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 317. BRAZIL NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2018-2024 (USD MILLION)
  • TABLE 318. BRAZIL NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2025-2032 (USD MILLION)
  • TABLE 319. BRAZIL NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 320. BRAZIL NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 321. BRAZIL NEWBORN SCREENING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 322. BRAZIL NEWBORN SCREENING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 323. BRAZIL NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 324. BRAZIL NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 325. UNITED KINGDOM NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 326. UNITED KINGDOM NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 327. UNITED KINGDOM NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2018-2024 (USD MILLION)
  • TABLE 328. UNITED KINGDOM NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2025-2032 (USD MILLION)
  • TABLE 329. UNITED KINGDOM NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 330. UNITED KINGDOM NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 331. UNITED KINGDOM NEWBORN SCREENING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 332. UNITED KINGDOM NEWBORN SCREENING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 333. UNITED KINGDOM NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 334. UNITED KINGDOM NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 335. GERMANY NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 336. GERMANY NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 337. GERMANY NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2018-2024 (USD MILLION)
  • TABLE 338. GERMANY NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2025-2032 (USD MILLION)
  • TABLE 339. GERMANY NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 340. GERMANY NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD